Kodiak Sciences (KOD) Why AMD fueled the stock 180% Higher
Kodiak Sciences stock surged over 170% following encouraging Phase 3 trial data for wet age-related macular degeneration treatments Zenkuda and KSI-501, which successfully met primary endpoints.








